The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).
Elahe A. Mostaghel
Honoraria - Janssen-Ortho
Brett Marck
No relevant relationships to disclose
Alvin M. Matsumoto
No relevant relationships to disclose
Daniel Tamae
No relevant relationships to disclose
Trevor M. Penning
Employment or Leadership Position - Penzymes
Consultant or Advisory Role - Tokai
Stock Ownership - Penzymes
Honoraria - Congress of Steroid Research
Steven P. Balk
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson
Research Funding - Tokai
Philip W. Kantoff
Consultant or Advisory Role - Janssen Research & Development
Research Funding - Janssen Research & Development
Peter Nelson
Consultant or Advisory Role - Astellas Pharma; Janssen Research & Development
Mary-Ellen Taplin
Consultant or Advisory Role - Janssen Research & Development
Honoraria - Janssen Research & Development
Research Funding - Janssen Research & Development
Robert B. Montgomery
Research Funding - Janssen Research & Development